MPB Business Summary

MegaPro Biomedical Co., Ltd. (MPB) is a Taiwan-based clinical-stage biopharmaceutical company specializing in the development of niche nanomedicines through its proprietary Nanoparticle™ and NanoMicelle™ technology platforms. The company operates an asset-light business model, generating revenue primarily through strategic product licensing, technology transfers, and collaborative development agreements with domestic and international pharmaceutical partners. Its primary business segments include diagnostic imaging, focused on non-heavy metal MRI contrast agents like MPB-1523 for liver cancer and MPB-2043 for lymph node staging, and therapeutics, which includes MPB-1514 for iron deficiency anemia and the oncology formulation MPB-1734. MPB competes directly with other specialized biotech firms such as Ever Supreme Bio Technology, Handa Pharma, PharmaEngine, and OBI Pharma, positioning itself as a high-barrier innovator in the global nanomedicine market by addressing safety and efficacy limitations of conventional treatments. Originally spun off from the Industrial Technology Research Institute (ITRI) in 2014, MPB is led by a founding team of veteran scientists and executives with deep pedigrees in chemical engineering and drug delivery. The leadership team is currently headed by CEO Dr. Hsien-Chih (Jassy) Wang and President Dr. Yuan-Hung Hsu, both of whom were instrumental in the company's transition from an ITRI research project to a publicly listed entity on the Taipei Exchange. The company maintains strong institutional backing from notable investors and strategic partners, including ITRI, China Chemical & Pharmaceutical Co. (CCPC), and International CSRC Investment Holdings. The board of directors and executive suite are characterized by a high density of PhD-level expertise, particularly in nanoparticle synthesis and clinical trial management, which continues to drive the company's pipeline toward late-stage regulatory milestones.